Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 134 (5), 1428-1435

The Role of IL-32 in Cutaneous T-cell Lymphoma

Affiliations

The Role of IL-32 in Cutaneous T-cell Lymphoma

Hiraku Suga et al. J Invest Dermatol.

Abstract

IL-32 is a pro-inflammatory cytokine expressed by activated natural killer cells, T cells, keratinocytes, and fibroblasts. In this study, we examined the role of IL-32 in cutaneous T-cell lymphoma (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS). IL-32 mRNA expression levels in lesional skin of MF patch, plaque, and tumor were increased compared with those of normal skin, which positively correlated with CCL17 and CCL18 mRNA expression levels. Serum IL-32 levels positively correlated with disease activity within each patient. Immunostaining showed that keratinocytes expressed IL-32 in the lesional skin of MF patch and plaque, whereas in MF tumor, atypical T cells in the dermis strongly expressed IL-32. We also showed that IL-32 dose-dependently accelerated the proliferation of MF and SS cell lines in vitro, which was inhibited by blocking mitogen-activated protein kinase and NF-κB-mediated signaling. The addition of anti-IL-32 antibodies in culture decreased the proliferation of SS cells and the viability of MF cells, suggesting that IL-32 serves as an autocrine growth factor. In conclusion, our results suggest that IL-32 has a role in the formation and maintenance of CTCL lesions, providing a possible therapeutic target for patients with this disease.

Similar articles

See all similar articles

Cited by 11 PubMed Central articles

See all "Cited by" articles

References

    1. J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e60-7 - PubMed
    1. J Invest Dermatol. 2010 Sep;130(9):2304-11 - PubMed
    1. Immunology. 2012 Jan;135(1):63-72 - PubMed
    1. Immunity. 2005 Jan;22(1):131-42 - PubMed
    1. J Am Acad Dermatol. 2003 Jan;48(1):23-30 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback